Material weakness
high
Filing comparison
BRAINSTORM CELL THERAPEUTICS INC. reported a material weakness in internal control
Internal control reported effective → Material weakness in internal control
… and product liability claims and litigation, adverse developments affecting the financial services industry, political instability, unrest and wars, such as the conflicts involving Ukraine and Russia and Israel and its surrounding regions, including our clinical development activities, our ability to improve our internal control over financial reporting, including our inability to remediate the identified material weakness, as well as the costs and the time associated with such efforts, and other factors…
Evidence
- Current state
- material_weakness
- Current state label
- Material weakness in internal control
- Direction
- newly reported
- Prior filed
- 2025-03-31
- Prior form
- 10-K
- Prior state
- effective
- Prior state label
- Internal control reported effective
- Remediation stated
- Yes
- Severity
- high
- Source
- Item 9A internal control conclusion, compared with the prior filing
- Why
- The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.